Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TVTX

Travere Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for TVTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.45

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:51 UTC.

What Travere Therapeutics, Inc. does

The company is a biopharmaceutical company headquartered in San Diego, California that focuses on identifying, developing, and delivering therapies for people with rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), received full FDA approval for slowing kidney function decline in adults with primary Immunoglobulin A nephropathy and is in late-stage development for focal segmental glomerulosclerosis.

Summarized from Travere Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.45

Revenue, margins & earnings

FY2021: net loss $180M on revenue $132M$132MFY2021FY2022: net loss $278M on revenue $109M$109MFY2022FY2023: net loss $111M on revenue $145M$145MFY2023FY2024: net loss $322M on revenue $233M$233MFY2024FY2025: net loss $26M on revenue $491M$491MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-19
  • 2026-10-19CHIEF EXECUTIVE OFFICERSale-128,065$6.78M
  • 2026-10-19CHIEF EXECUTIVE OFFICEROption exercise200,000$1.79M
  • 2026-10-19CHIEF EXECUTIVE OFFICEROption exercise43,735$1.18M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Travere Therapeutics, Inc. do?

The company is a biopharmaceutical company headquartered in San Diego, California that focuses on identifying, developing, and delivering therapies for people with rare kidney and metabolic diseases.

When did TVTX last file with the SEC?

Travere Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-09. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:51 UTC. This page is also available as JSON at /api/data?ticker=TVTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TVTX and 5,000+ tickers.

Create a free account — keep TVTX
For your agent
GET /api/data?ticker=TVTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt